Sporadic or late onset Alzheimer’s disease (LOAD) is a multifactorial neurodegenerative disease with aging the most known risk factor. Non-human primates (NHPs) may serve as an excellent model to study LOAD because of their close similarity to humans in many aspects including neuroanatomy and neurodevelopment. Recent studies reveal AD-like pathology in old NHPs.
Objective:
In this pilot study, we took advantage of brain samples from 6 Cynomolgus macaques that were divided into two groups: middle aged (average age 14.81 years) and older (average age 19.33 years). We investigated whether AD-like brain pathologies are present in the NHPs.
Methods:
We used immunohistochemical method to examine brain Aβ pathology and neuron density. We applied biochemical assays to measure tau phosphorylation and multiple signaling pathways indicated in AD. We performed electron microscopy experiments to study alterations of postsynaptic density and mitochondrial morphology in the brain of NHPs.
Results:
We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK), decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation.
Conclusion:
These findings may provide insights into the factors contributing to the development of LOAD, particularly during the early stage transitioning from middle to old age. Future endeavors are warranted to elucidate mechanisms underlying the regional (and perhaps cellular) vulnerability with aging and the functional correlation of such pathological changes in NHPs.
MufsonEJ, IkonomovicMD, CountsSE, PerezSE, Malek-AhmadiM, ScheffSW, GinsbergSD (2016) Molecular and cellular pathophysiology of preclinical Alzheimer’s disease. Behav Brain Res311, 54–69.
15.
WangX, ZimmermannHR, LockhartSN, CraftS, MaT (2020) Decreased levels of blood AMPKα1 but not AMPK α 2 isoform in patients with mild cognitive impairment and Alzheimer’s Disease: A pilot study. J Alzheimers Dis76, 217–224.
DeKoskyST, ScheffSW, StyrenSD (1996) Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration5, 417–421.
18.
Guerrero-MuñozMJ, GersonJ, Castillo-CarranzaDL (2015) Tau oligomers: The toxic player at synapses in Alzheimer’s disease. Front Cell Neurosci9, 464.
19.
MaT, HoefferCA, WongH, MassaadCA, ZhouP, IadecolaC, MurphyMP, PautlerRG, KlannE (2011) Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J Neurosci31, 5589–5595.
NavarroA, BoverisA (2007) The mitochondrial energy transduction system and the aging process. , Am J Physiol Cell Physiol292, C670–C686.
22.
BoffoliD, ScaccoSC, VergariR, SolarinoG, SantacroceG, PapaS (1994) Decline with age of the respiratory chain activity in human skeletal muscle. Biochim Biochys Acta1226, 73–82.
23.
HardieDG (2011) Sensing of energy and nutrients by AMP-activated protein kinase, Am J Clin Nutr93,891S–896S.
24.
HardieDG, RossFA, HawleySA (2012) AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol13, 251–262.
25.
YanY, ZhouX, XuH, MelcherK (2018) Structure and physiological regulation of AMPK. Int J Mol Sci19, 3534.
26.
SalminenA, KaarnirantaK, KauppinenA (2016) Age-related changes in AMPK activation: Role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways. Ageing Res Rev28, 15–26.
27.
MaT, ChenY, VingtdeuxV, ZhaoH, ViolletB, MarambaudP, KlannE (2014) Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β. J Neurosci34, 12230–12238.
28.
DomiseM, Sauvée F, DidierS, CaillerezR, Béegard S, CarrierS, ColinM, MarinangeliC, Buéee L, VingtdeuxV (2019) Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process. Cell Death Dis10, 221.
29.
DomiseM, DidierS, MarinangeliC, ZhaoH, ChandakkarP, BuéeeL, ViolletB, DaviesP, MarambaudP, VingtdeuxV (2016) AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep6, 26758.
30.
VingtdeuxV, DaviesP, DicksonDW, MarambaudP (2011) AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies. Acta Neuropathol121, 337–349.
WangW, ZhaoF, MaX, PerryG, ZhuX (2020) Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances. Mol Neurodegener15, 30.
33.
BealMF (2007) Mitochondria and neurodegeneration. , 183-192; discussion, Novartis Found Symp287, 192–186.
34.
LinMT, BealMF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature443, 787–795.
35.
ColmanRJ (2018) Non-human primates as a model for aging. Biochim Biophys Acta Mol Basis Dis1864, 2733–2741.
36.
LiHW, ZhangL, QinC (2019) Current state of research on non-human primate models of Alzheimer’s disease. Animal Models Exp Med2, 227–238.
37.
ArnstenAFT, DattaD, LeslieS, YangS-T, WangM, NairnAC (2019) Alzheimer’s-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimer’s disease. Proc Natl Acad Sci U S A116, 26230–26238.
38.
NakamuraS, NakayamaH, GotoN, OnoF, SakakibaraI, YoshikawaY (1998) Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys. J Med Primatol27, 244–252.
39.
WuJ, BashaMR, BrockB, CoxDP, Cardozo-PelaezF, McPhersonCA, HarryJ, RiceDC, MaloneyB, ChenD, LahiriDK, ZawiaNH (2008) Alzheimer’s disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): Evidence for a developmental origin and environmental link for AD. J Neurosci28, 3–9.
40.
OikawaN, KimuraN, YanagisawaK (2010) Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. Brain Res1315, 137–149.
41.
LatimerCS, ShivelyCA, KeeneCD, JorgensenMJ, AndrewsRN, RegisterTC, MontineTJ, WilsonAM, NethBJ, MintzA, MaldjianJA, WhitlowCT, KaplanJR, CraftS (2019) A nonhuman primate model of early Alzheimer’s disease pathologic change: Implications for disease pathogenesis. Alzheimers Dement15, 93–105.
42.
WangX, ZhouX, UbersederB, LeeJ, LatimerCS, FurduiCM, KeeneCD, MontineTJ, RegisterTC, CraftS, ShivelyCA, MaT (2021) Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer’s disease. Neurobiol Dis158, 105463.
43.
OstroffLE, FialaJC, AllwardtB, HarrisKM (2002) Polyribosomes redistribute from dendritic shafts into spines with enlarged synapses during LTP in developing rat hippocampal slices. Neuron35, 535–545.
44.
OstroffLE, WatsonDJ, CaoG, ParkerPH, SmithH, HarrisKM (2018) Shifting patterns of polyribosome accumulation at synapses over the course of hippocampal long-term potentiation. Hippocampus28, 416–430.
45.
MartinsIV, Rivers-AutyJ, AllanSM, LawrenceCB (2017) Mitochondrial Abnormalities and synaptic loss underlie memory deficits seen in mouse models of obesity and Alzheimer’s disease. J Alzheimers Dis55, 915–932.
46.
AugustinackJC, SchneiderA, MandelkowEM, HymanBT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol103, 26–35.
47.
KimuraT, OnoT, TakamatsuJ, YamamotoH, IkegamiK, KondoA, HasegawaM, IharaY, MiyamotoE, MiyakawaT (1996) Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dement Geriatr Cogn Disord7, 177–181.
48.
NeddensJ, TemmelM, FlunkertS, KerschbaumerB, HoellerC, LoefflerT, NiederkoflerV, DaumG, AttemsJ, Hutter-PaierB (2018) Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun6, 52.
49.
ZimmermannHR, YangW, KasicaNP, ZhouX, WangX, BeckelmanBC, LeeJ, FurduiCM, KeeneCD, MaT (2020) Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer’s model mice. J Clin Invest130, 3511–3527.
50.
ThorntonC, BrightNJ, SastreM, MuckettPJ, CarlingD (2011) AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J434, 503–512.
51.
WagnerU, UttonM, GalloJM, MillerCC (1996) Cellular phosphorylation of tau by GSK-3β influences tau binding to microtubules and microtubule organisation. J Cell Sci109, 1537–1543.
52.
SperberBR, LeightS, GoedertM, LeeVM (1995) Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett197, 149–153.
53.
HernandezF, LucasJJ, AvilaJ (2013) GSK3 and Tau: Two convergence points in Alzheimer’s disease. J Alzheimers Dis33, 141–144.
54.
MartinL, LatypovaX, WilsonCM, MagnaudeixA, PerrinML, TerroF (2013) Tau protein phosphatases in Alzheimer’s disease: The leading role of PP2A. Ageing Res Rev12, 39–49.
ReddyPH, BealMF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med14, 45–53.
60.
CaoK, DongYT, XiangJ, XuY, HongW, SongH, GuanZZ (2018) Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer’s disease. J Clin Pathol71, 1090–1099.
61.
WojsiatJ, ZoltowskaKM, Laskowska-KaszubK, WojdaU (2018) Oxidant/antioxidant imbalance in Alzheimer’s disease: Therapeutic and diagnostic prospects. Oxid Med Cell Longev2018, 6435861.
62.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
63.
OverkCR, MasliahE (2014) Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem Pharmacol88, 508–516.
64.
FornerS, Baglietto-VargasD, MartiniAC, Trujillo-EstradaL, LaferlaFM (2017) Synaptic impairment in Alzheimer’s disease: A dysregulated symphony. Trends Neurosci40, 347–357.
65.
ScheffSW, PriceDA, SchmittFA, MufsonEJ (2006) Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging27, 1372–1384.
66.
KnoblochM, MansuyIM (2008) Dendritic spine loss and synaptic alterations in Alzheimer’s disease. Mol Neurobiol37, 73–82.
67.
ShengM, KimE (2011) The postsynaptic organization of synapses. , a, Cold Spring Harb Perspect Biol3, 005678.
68.
PuzzoD, GulisanoW, PalmeriA, ArancioO (2015) Rodent models for Alzheimer’s disease drug discovery. Expert Opinion Drug Discov10, 703–711.
69.
VanDam D, DeDeyn PP (2017) Non human primate models for Alzheimer’s disease-related research and drug discovery. Expert Opinion Drug Discov12, 187–200.
CramerPE, GentzelRC, TanisKQ, VardiganJ, WangY, ConnollyB, ManfreP, LodgeK, RengerJJ, ZerbinattiC, UslanerJM (2018) Aging African monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer’s disease. Neurobiol Aging64, 92–106green.
72.
SmallSA, DuffK (2008) Linking Aβ and tau in late-onset Alzheimer’s disease: A dual pathway hypothesis. Neuron60, 534–542.
73.
ArnstenAFT, DattaD, Del TrediciK, BraakH (2021) Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimers Dement17, 115–124.
74.
BraakH, ThalDR, GhebremedhinE, DelTredici K (2011) Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol70, 960–969.
75.
BraakH, DelTredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol121, 171–181.
76.
DarusmanHS, GjeddeA, SajuthiD, SchapiroSJ, KalliokoskiO, KristianingrumYP, HandaryaniE, HauJ (2014) Amyloid beta1-42 and the phosphorylated tau threonine 231 in brains of aged Cynomolgus monkeys (Macaca fascicularis). Front Aging Neurosci6, 313.
77.
ElderGA, Gama SosaMA, De Gasperi R (2010) Transgenic mouse models of Alzheimer’s disease. Mt Sinai J Med77, 69–81.
78.
PoduriA, GearingM, RebeckGW, MirraSS, TiggesJ, HymanBT (1994) Apolipoprotein E4 and beta amyloid in senile plaques and cerebral blood vessels of aged rhesus monkeys. Am J Pathol144, 1183–1187.
HeilbronerPL, KemperTL (1990) The cytoarchitectonic distribution of senile plaques in three aged monkeys. Acta Neuropathol81, 60–65.
81.
SaniS, TraulD, KlinkA, NiarakiN, Gonzalo-RuizA, WuC-K, GeulaC (2003) Distribution, progression and chemical composition of cortical amyloid-β deposits in aged rhesus monkeys: Similarities to the human. Acta Neuropathol105, 145–156.
82.
WangX, ZhouX, UbersederB, LeeJ, LatimerCS, FurduiCM, KeeneCD, MontineTJ, RegisterTC, CraftS, ShivelyCA, MaT (2021) Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer’s disease. Neurobiol Dis158, 105463.
SalatDH, KayeJA, JanowskyJS (2001) Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease. Arch Neurol58, 1403.
85.
YangF, DiaoX, WangF, WangQ, SunJ, ZhouY, XieJ (2020) Identification of key regulatory genes and pathways in prefrontal cortex of Alzheimer’s disease. Interdiscip Sci12, 90–98.
86.
AlexanderGE, BergfieldKL, ChenK, ReimanEM, HansonKD, LinL, BandyD, CaselliRJ, MoellerJR (2012) Gray matter network associated with risk for Alzheimer’s disease in young to middle-aged adults. Neurobiol Aging33, 2723–2732.
87.
HuW, WuF, ZhangY, GongCX, IqbalK, LiuF (2017) Expression of tau pathology-related proteins in different brain regions: A molecular basis of tau pathogenesis. Front Aging Neurosci9, 311.
88.
KleinHU, TrumpffC, YangHS, LeeAJ, PicardM, BennettDA, De JagerPL (2021) Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain. Mol Neurodegener16, 75.
89.
OkabeS (2007) Molecular anatomy of the postsynaptic density. Mol Cell Neurosci34, 503–518.
90.
ArellanoJI, Benavides-PiccioneR, DefelipeJ, YusteR (2007) Ultrastructure of dendritic spines: Correlation between synaptic and spine morphologies. Front Neurosci1, 131–143.
91.
BourneJ, HarrisKM (2007) Do thin spines learn to be mushroom spines that remember? Curr Opin Neurobiol17, 381–386.
92.
KasaiH, HayamaT, IshikawaM, WatanabeS, YagishitaS, NoguchiJ (2010) Learning rules and persistence of dendritic spines. Eur J Neurosci32, 241–249.
93.
NeumanKM, Molina-CamposE, MusialTF, PriceAL, OhK-J, WolkeML, BussEW, ScheffSW, MufsonEJ, NicholsonDA (2015) Evidence for Alzheimer’s disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Struct Funct220, 3143–3165.
94.
ScheffSW, PriceDA, SchmittFA, DekoskyST, MufsonEJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology68, 1501–1508.
95.
DumitriuD, HaoJ, HaraY, KaufmannJ, JanssenWGM, LouW, RappPR, MorrisonJH (2010) Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment. J Neurosci30, 7507–7515.
96.
MorrisonJH, BaxterMG (2012) The ageing cortical synapse: Hallmarks and implications for cognitive decline. Nat Rev Neurosci13, 240–250.
97.
PotterWB, O’RiordanKJ, BarnettD, OstingSMK, WagonerM, BurgerC, RoopraA (2010) Metabolic regulation of neuronal plasticity by the energy sensor AMPK, PLoS One5, e8996.
98.
WeiH, ZhangHL, WangXC, XieJZ, AnDD, WanL, WangJZ, ZengY, ShuXJ, WestermarckJ, LuYM, OhlmeyerM, LiuR (2020) Direct activation of protein phosphatase 2A (PP2A) by tricyclic sulfonamides ameliorates Alzheimer’s disease pathogenesis in cell and animal models. Neurotherapeutics17, 1087–1103.
99.
LeongW, XuW, WangB, GaoS, ZhaiX, WangC, GilsonE, YeJ, LuY (2020) PP2A subunit PPP2R2C is downregulated in the brains of Alzheimer’s transgenic mice. Aging12, 6880–6890.
100.
NichollsRE, SontagJM, ZhangH, StaniszewskiA, YanS, KimCY, YimM, WoodruffCM, ArningE, WasekB, YinD, BottiglieriT, SontagE, KandelER, ArancioO (2016) PP2A methylation controls sensitivity and resistance to β-amyloid– induced cognitive and electrophysiological impairments. Proc Natl Acad Sci U S A113, 3347–3352.
